---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-245093"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T03:01:34.917079+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galera sells avasopasem/rucosopasem assets to Biossil for $3.5M upfront, up to $105M milestones

## Summary
- Biossil Inc. acquires all of Galera's dismutase mimetic assets, including avasopasem (GC4419) and rucosopasem (GC4711).
- Upfront payment of $3,500,000; potential regulatory/commercial milestones and contingent value rights total up to $105,000,000.
- Biossil assumes rights and obligations under the 2018 Clarus IV Galera Royalty agreement (affiliated with Blackstone Life Sciences).
- Purchase Agreement contains customary representations, warranties, and covenants; filing of full agreement will follow in next Form 10-Q.

## SEC filing metadata
- accession: 0001193125-25-245093
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312525245093/0001193125-25-245093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312525245093/d96389d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-245093
- JSON: https://secwatch.observer/filing/0001193125-25-245093.json
- Plain text: https://secwatch.observer/filing/0001193125-25-245093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.